Latest Period
Q4 2025
Security Snapshot
Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (JSPR) Institutional Ownership
CUSIP: 471871202
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
53
Shares (Excl. Options)
19,220,734
Price
$1.83
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Voting Common Stock, par value $0.0001 per share
- Symbol
- JSPR on Nasdaq
- Shares outstanding
- 28,086,431
- Price per share
- $0.92
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 19,220,734
- Total reported value
- $35,163,686
- % of total 13F portfolios
- 0%
- Share change
- -5,665
- Value change
- -$2,365,311
- Number of holders
- 53
- Price from insider filings
- $0.92
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- JSPR - Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share is tracked under CUSIP 471871202.
- 53 institutions reported positions in Q4 2025.
- 11 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 53 to 5 between Q4 2025 and Q1 2026.
- Reported value moved from $35,163,686 to $111,257.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 53 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 471871202?
CUSIP 471871202 identifies JSPR - Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 471871202:
Significant Owners of Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (JSPR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 9.6% | $7,578,242 | 2,668,395 | Velan Capital Investment Management LP | 19 Sep 2025 | |||
| T. Rowe Price Investment Management, Inc. | 7.1% | $4,897,117 | 2,057,612 | T. Rowe Price Investment Management, Inc. | 30 Sep 2025 | |||
| MORGAN STANLEY | 7% | +140% | $3,269,843 | +$1,967,361 | 1,969,785 | +151% | Morgan Stanley | 31 Dec 2025 |
| GOLDMAN SACHS GROUP INC | 6.3% | $2,929,648 | 1,764,848 | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 5.8% | $2,492,390 | 1,629,013 | Millennium Management LLC | 18 Feb 2026 | |||
| Soleus Capital Master Fund, L.P. | 10% | $7,068,607 | 1,494,420 | Soleus Capital Management, L.P. | 31 Dec 2024 | |||
| ACORN BIOVENTURES, L.P. | 5.3% | -18% | $2,660,821 | -$537,000 | 1,486,492 | -17% | Anders Hove | 23 Jan 2026 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 4.7% | -8% | $3,153,131 | +$1,332,431 | 1,324,845 | +73% | Kingdon Capital Management, L.L.C. | 30 Sep 2025 |
| Carlyle Group Inc. | 3.8% | $1,665,114 | 1,088,310 | The Carlyle Group Inc. | 18 Feb 2026 | |||
| Qiming U.S. Healthcare Fund II, L.P. | 3.3% | $2,210,934 | 928,964 | Qiming U.S. Healthcare Fund II, L.P. | 30 Sep 2025 | |||
| BlackRock, Inc. | 1.5% | $1,252,311 | 225,605 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 53 institutional investors reported holding 19,220,734 shares of Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (JSPR). This represents 68% of the company’s total 28,086,431 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (JSPR) together control 67% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 9.5% | 2,668,395 | 0% | 2.8% | $4,883,163 |
| MORGAN STANLEY | 7% | 1,969,785 | +149% | 0% | $3,604,707 |
| ACORN CAPITAL ADVISORS, LLC | 6.4% | 1,786,492 | +29% | 1.1% | $3,269,280 |
| GOLDMAN SACHS GROUP INC | 6.2% | 1,746,492 | +6395% | 0% | $3,196,080 |
| VANGUARD GROUP INC | 4.7% | 1,326,512 | +28% | 0% | $2,427,518 |
| Rock Springs Capital Management LP | 3.9% | 1,100,726 | 0% | 0.1% | $2,014,329 |
| MILLENNIUM MANAGEMENT LLC | 3.8% | 1,073,783 | +194% | 0% | $1,965,023 |
| Carlyle Group Inc. | 3.8% | 1,066,189 | 0% | 0.01% | $1,940,464 |
| Woodline Partners LP | 3.7% | 1,040,704 | +0.09% | 0.01% | $1,904,488 |
| T. Rowe Price Investment Management, Inc. | 3.4% | 964,754 | -6.2% | 0% | $1,766,000 |
| BOOTHBAY FUND MANAGEMENT, LLC | 2.8% | 793,954 | +79% | 0.04% | $1,452,936 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.7% | 485,401 | -23% | 0.19% | $888,284 |
| Lion Point Capital, LP | 1.7% | 465,000 | +17% | 4.4% | $850,950 |
| BANK OF AMERICA CORP /DE/ | 1% | 293,027 | -0.52% | 0% | $536,239 |
| Squarepoint Ops LLC | 1% | 281,926 | +1920% | 0% | $515,925 |
| BlackRock, Inc. | 0.84% | 236,224 | +15% | 0% | $432,290 |
| RENAISSANCE TECHNOLOGIES LLC | 0.81% | 227,183 | +9% | 0% | $415,745 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.75% | 211,857 | +62% | 0% | $387,788 |
| Soleus Capital Management, L.P. | 0.71% | 200,000 | -87% | 0.02% | $366,000 |
| Knott David M Jr | 0.65% | 181,389 | +5.8% | 0.15% | $331,942 |
| ADAR1 Capital Management, LLC | 0.5% | 140,000 | 0.02% | $256,200 | |
| UBS Group AG | 0.45% | 126,361 | +221% | 0% | $231,240 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.37% | 104,787 | +194% | 0% | $191,760 |
| Quarry LP | 0.35% | 99,529 | 0.04% | $182,138 | |
| READYSTATE ASSET MANAGEMENT LP | 0.35% | 98,439 | 0% | 0.01% | $180,143 |
Institutional Holders of Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (JSPR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 126,996 | $111,257 | -$26,797 | $0.88 | 5 |
| 2025 Q4 | 19,220,734 | $35,163,686 | -$2,365,311 | $1.83 | 53 |
| 2025 Q3 | 20,155,363 | $47,814,871 | +$13,375,643 | $2.38 | 60 |
| 2025 Q2 | 12,514,434 | $69,456,410 | -$2,535,024 | $5.55 | 63 |
| 2025 Q1 | 13,034,173 | $56,047,183 | -$70,633,595 | $4.30 | 66 |
| 2024 Q4 | 15,646,434 | $334,368,683 | +$15,008,656 | $21.38 | 84 |
| 2024 Q3 | 14,676,954 | $274,620,688 | -$5,485,865 | $18.81 | 77 |
| 2024 Q2 | 14,557,013 | $329,580,756 | +$34,893,415 | $22.70 | 67 |
| 2024 Q1 | 12,950,959 | $379,146,145 | +$364,621,578 | $29.36 | 56 |
| 2023 Q4 | 494,706 | $390,323 | +$390,323 | $0.79 | 1 |